TGTX Total Assets from 2010 to 2024

TGTX Stock

USD 34.80 0.20 0.57%

TG Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

1996-06-30

Previous Quarter

401.2 M

Current Value

586 M

Quarterly Volatility

135.4 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 444.1 K, Interest Expense of 13.2 M or Total Revenue of 245.3 M, as well as many indicators such as Price To Sales Ratio of 9.86, Dividend Yield of 4.0E-4 or PTB Ratio of 15.86. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.

Check out the analysis of TG Therapeutics Correlation against competitors.

For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

Latest TG Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of TG Therapeutics over the last few years. Total assets refers to the total amount of TG Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in TG Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. TG Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TG Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 329.59 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

TGTX Total Assets Regression Statistics

	Arithmetic Mean	170,800,214
	Geometric Mean	88,204,687
	Coefficient Of Variation	103.00
	Mean Deviation	136,066,037
	Median	97,381,536
	Standard Deviation	175,931,492
	Sample Variance	30951.9T
	Range	623.2M
	R-Value	0.75
	Mean Square Error	14788.6T
	R-Squared	0.56
	Significance	0
	Slope	29,342,502
	Total Sum of Squares	433326.5T

TGTX Total Assets History

	2024	346.1 M
	2023	329.6 M
	2022	193.6 M
	2021	379.6 M
	2020	625.6 M
	2019	163 M
	2018	83.6 M

Other Fundumenentals of TG Therapeutics

Intangibles To Total Assets

TG Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Net Receivables	Accounts Payable	Common Stock	Property Plant Equipment	Short Term Investments	Long Term Debt	Short Term Debt	Current Deferred Revenue	Intangible Assets	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Treasury Stock	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.03	-0.74	-0.75	0.69	1.0	0.39	0.52	-0.08	0.76	0.59	0.52	0.82	-0.01	-0.36	0.88	0.47	0.46	0.84	-0.39	-0.43	0.04	0.75	0.96	0.96	0.84
Total Stockholder Equity	-0.03		-0.07	0.44	-0.29	0.02	0.22	-0.02	-0.05	-0.34	0.09	-0.37	0.17	-0.27	0.1	0.03	0.01	-0.42	-0.31	0.28	0.16	-0.47	0.3	0.06	0.11	-0.38
Net Debt	-0.74	-0.07		0.21	-0.16	-0.75	0.27	-0.13	0.05	-0.5	0.05	0.14	-0.92	0.0	0.19	-0.94	-0.05	0.18	-0.31	0.09	0.27	-0.12	-0.91	-0.81	-0.8	-0.35
Retained Earnings	-0.75	0.44	0.21		-0.85	-0.74	-0.6	-0.7	0.05	-0.77	-0.79	-0.91	-0.34	-0.05	0.37	-0.42	-0.59	-0.87	-0.98	0.47	0.45	-0.03	-0.24	-0.61	-0.61	-0.96
Total Liab	0.69	-0.29	-0.16	-0.85		0.67	0.6	0.64	-0.32	0.61	0.79	0.77	0.21	0.18	-0.57	0.38	0.75	0.86	0.86	-0.26	-0.7	0.18	0.13	0.48	0.48	0.79
Total Current Assets	1.0	0.02	-0.75	-0.74	0.67		0.4	0.54	-0.07	0.74	0.61	0.51	0.83	-0.01	-0.35	0.88	0.47	0.43	0.83	-0.38	-0.42	-0.01	0.78	0.96	0.96	0.83
Net Receivables	0.39	0.22	0.27	-0.6	0.6	0.4		0.48	0.0	0.29	0.91	0.79	-0.04	-0.1	-0.15	-0.01	0.57	0.7	0.64	-0.38	-0.12	-0.27	-0.06	0.3	0.32	0.57
Accounts Payable	0.52	-0.02	-0.13	-0.7	0.64	0.54	0.48		-0.19	0.49	0.76	0.58	0.34	0.18	-0.41	0.19	0.57	0.55	0.7	-0.07	-0.51	-0.5	0.32	0.35	0.38	0.59
Common Stock	-0.08	-0.05	0.05	0.05	-0.32	-0.07	0.0	-0.19		0.12	-0.11	0.01	0.02	-0.05	0.9	-0.06	-0.71	-0.14	-0.06	-0.67	0.73	-0.09	0.03	0.05	0.04	0.04
Property Plant Equipment	0.76	-0.34	-0.5	-0.77	0.61	0.74	0.29	0.49	0.12		0.46	0.58	0.48	0.08	-0.15	0.63	0.34	0.58	0.78	-0.31	-0.39	0.01	0.4	0.69	0.67	0.75
Short Term Investments	0.59	0.09	0.05	-0.79	0.79	0.61	0.91	0.76	-0.11	0.46		0.84	0.2	-0.05	-0.33	0.18	0.69	0.8	0.83	-0.35	-0.37	-0.26	0.16	0.45	0.48	0.74
Long Term Debt	0.52	-0.37	0.14	-0.91	0.77	0.51	0.79	0.58	0.01	0.58	0.84		0.02	0.01	-0.26	0.11	0.56	0.92	0.88	-0.5	-0.28	0.0	-0.08	0.37	0.37	0.84
Short Term Debt	0.82	0.17	-0.92	-0.34	0.21	0.83	-0.04	0.34	0.02	0.48	0.2	0.02		-0.05	-0.15	0.9	0.1	-0.09	0.45	-0.26	-0.18	-0.12	0.99	0.88	0.89	0.5
Current Deferred Revenue	-0.01	-0.27	0.0	-0.05	0.18	-0.01	-0.1	0.18	-0.05	0.08	-0.05	0.01	-0.05		-0.1	-0.12	0.04	-0.03	0.01	-0.1	-0.14	-0.19	-0.08	-0.14	-0.14	0.04
Intangible Assets	-0.36	0.1	0.19	0.37	-0.57	-0.35	-0.15	-0.41	0.9	-0.15	-0.33	-0.26	-0.15	-0.1		-0.25	-0.76	-0.38	-0.38	-0.39	0.81	-0.09	-0.11	-0.2	-0.2	-0.29
Net Tangible Assets	0.88	0.03	-0.94	-0.42	0.38	0.88	-0.01	0.19	-0.06	0.63	0.18	0.11	0.9	-0.12	-0.25		0.2	0.09	0.53	-0.23	-0.33	0.22	0.86	0.92	0.91	0.56
Good Will	0.47	0.01	-0.05	-0.59	0.75	0.47	0.57	0.57	-0.71	0.34	0.69	0.56	0.1	0.04	-0.76	0.2		0.63	0.61	0.24	-0.78	-0.04	0.07	0.31	0.32	0.51
Long Term Debt Total	0.46	-0.42	0.18	-0.87	0.86	0.43	0.7	0.55	-0.14	0.58	0.8	0.92	-0.09	-0.03	-0.38	0.09	0.63		0.83	-0.33	-0.46	0.18	-0.18	0.27	0.26	0.75
Capital Surpluse	0.84	-0.31	-0.31	-0.98	0.86	0.83	0.64	0.7	-0.06	0.78	0.83	0.88	0.45	0.01	-0.38	0.53	0.61	0.83		-0.48	-0.45	0.01	0.35	0.71	0.71	0.97
Deferred Long Term Liab	-0.39	0.28	0.09	0.47	-0.26	-0.38	-0.38	-0.07	-0.67	-0.31	-0.35	-0.5	-0.26	-0.1	-0.39	-0.23	0.24	-0.33	-0.48		-0.39	-0.11	-0.19	-0.43	-0.42	-0.61
Treasury Stock	-0.43	0.16	0.27	0.45	-0.7	-0.42	-0.12	-0.51	0.73	-0.39	-0.37	-0.28	-0.18	-0.14	0.81	-0.33	-0.78	-0.46	-0.45	-0.39		-0.15	-0.15	-0.24	-0.24	-0.34
Long Term Investments	0.04	-0.47	-0.12	-0.03	0.18	-0.01	-0.27	-0.5	-0.09	0.01	-0.26	0.0	-0.12	-0.19	-0.09	0.22	-0.04	0.18	0.01	-0.11	-0.15		-0.17	0.03	-0.02	0.06
Short Long Term Debt	0.75	0.3	-0.91	-0.24	0.13	0.78	-0.06	0.32	0.03	0.4	0.16	-0.08	0.99	-0.08	-0.11	0.86	0.07	-0.18	0.35	-0.19	-0.15	-0.17		0.84	0.85	0.39
Net Invested Capital	0.96	0.06	-0.81	-0.61	0.48	0.96	0.3	0.35	0.05	0.69	0.45	0.37	0.88	-0.14	-0.2	0.92	0.31	0.27	0.71	-0.43	-0.24	0.03	0.84		1.0	0.76
Net Working Capital	0.96	0.11	-0.8	-0.61	0.48	0.96	0.32	0.38	0.04	0.67	0.48	0.37	0.89	-0.14	-0.2	0.91	0.32	0.26	0.71	-0.42	-0.24	-0.02	0.85	1.0		0.75
Capital Stock	0.84	-0.38	-0.35	-0.96	0.79	0.83	0.57	0.59	0.04	0.75	0.74	0.84	0.5	0.04	-0.29	0.56	0.51	0.75	0.97	-0.61	-0.34	0.06	0.39	0.76	0.75

Click cells to compare fundamentals

About TG Therapeutics Financial Statements

TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	329.6 M	346.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC